General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 171: The ratio of the dose that produces toxicity to the dose that produces a clinically desired or effective response in a population of individuals is known as?

A. Efficacy
B. Potency
C. Therapeutic index (Correct Answer)
D. Partial agonist

Explanation: The correct answer is Therapeutic Index (TI). The Therapeutic Index is a quantitative measurement of the relative safety of a drug [1, 2]. It is defined as the ratio of the dose that produces toxicity to the dose that produces the desired therapeutic effect [1, 2]. In animal studies, it is calculated as $TI = TD_{50} / ED_{50}$ (where $TD_{50}$ is the toxic dose in 50% of the population and $ED_{50}$ is the effective dose in 50%) [1]. A higher TI indicates a wider safety margin, meaning the lethal/toxic dose is much higher than the therapeutic dose [1].Why other options are incorrect:Efficacy: Refers to the maximum response ($E_{max}$) a drug can produce, regardless of dose. It is a measure of a drug's intrinsic activity [2].Potency: Refers to the amount of drug (dose) required to produce an effect of a given intensity. It is usually measured by the $EC_{50}$ (the concentration producing 50% of the maximum effect) [2].Partial Agonist: A drug that binds to a receptor but produces only a sub-maximal response, even at 100% receptor occupancy. It has an intrinsic activity between 0 and 1.High-Yield Clinical Pearls for NEET-PG:Narrow Therapeutic Index (NTI) Drugs: These drugs require frequent Therapeutic Drug Monitoring (TDM) because small dose changes can lead to toxicity.Mnemonic: Warfarin, Theophylline, Digoxin, Lithium, Phenytoin (With The Dog Like People).Certainty Safety Factor: A more clinically relevant measure than TI, calculated as $LD_1 / ED_{99}$.Therapeutic Window: The range of drug dosages which can treat disease effectively without having toxic effects [1].

Question 172: Zero order kinetics means:

A. A constant amount of drug is eliminated per unit time (Correct Answer)
B. A constant fraction of the drug in the body is eliminated per unit time
C. The fraction of the administered dose that reaches the systemic circulation.
D. The effect that can be increased by giving a second agent that boosts the effect of the liver's enzyme system

Explanation: **Explanation:** **Zero-order kinetics** occurs when the rate of drug elimination is independent of the plasma concentration. This typically happens when the metabolic enzymes or transport systems responsible for elimination become **saturated** [1]. Therefore, a **constant amount** (e.g., 10 mg/hour) of the drug is eliminated per unit time, regardless of how much drug is in the body [2]. **Analysis of Options:** * **Option A (Correct):** This is the definition of zero-order kinetics. The elimination rate is constant (Rate = k). * **Option B (Incorrect):** This describes **First-order kinetics**, where a constant *fraction* or percentage (e.g., 10% per hour) is eliminated [2]. Most drugs follow first-order kinetics at therapeutic doses [1]. * **Option C (Incorrect):** This is the definition of **Bioavailability (F)**. * **Option D (Incorrect):** This refers to **Enzyme Induction**, which increases the rate of metabolism but does not define the order of kinetics. **High-Yield Clinical Pearls for NEET-PG:** 1. **Mnemonic for Zero-Order Drugs:** **"WATT"** or **"Zero WATTS"** * **W**arfarin (at high doses) * **A**lcohol (Ethanol) - *Most common example* [1] * **T**heophylline * **T**olbutamide * **S**alicylates (Aspirin) and **P**henytoin (at high doses) [1] 2. **Key Differences:** * **First-order:** Half-life ($t_{1/2}$) is constant. * **Zero-order:** Half-life ($t_{1/2}$) is not constant; it decreases as the concentration decreases. 3. **Capacity-limited elimination:** Zero-order kinetics is also known as "saturation" or "Michaelis-Menten" kinetics [2]. When a drug shifts from first-order to zero-order (like Phenytoin), it can lead to a sudden, toxic rise in plasma levels with small dose increases [1].

Question 173: Side effects of a drug arise due to interactions of the drug with molecules other than its target. These effects can be minimized by the drug's high:

A. Specificity (Correct Answer)
B. Solubility
C. Affinity
D. Hydrophobicity

Explanation: ### **Explanation** The correct answer is **A. Specificity**. **1. Why Specificity is Correct:** Specificity refers to the ability of a drug to interact with one particular receptor or target molecule while ignoring others. A drug with **high specificity** acts like a "precise key" that only fits into one specific "lock" (the target). Since side effects often arise from "off-target" interactions (the drug binding to unintended receptors in different tissues), increasing the specificity ensures the drug only triggers the desired pharmacological response, thereby minimizing adverse effects. **2. Why Other Options are Incorrect:** * **B. Solubility:** This refers to the drug's ability to dissolve in a solvent (lipid or water). While it affects absorption and distribution, it does not dictate whether a drug will bind to a specific receptor versus an unintended one. * **C. Affinity:** This describes the **strength** of the bond between a drug and its receptor. A drug can have high affinity for multiple receptors (e.g., Amitriptyline has high affinity for muscarinic, histaminic, and alpha-receptors), which actually *increases* the likelihood of side effects. High affinity does not guarantee selectivity. * **D. Hydrophobicity:** This relates to lipid solubility. Highly hydrophobic drugs cross the blood-brain barrier easily, which might actually increase CNS-related side effects rather than minimizing them. **3. NEET-PG High-Yield Pearls:** * **Selectivity vs. Specificity:** In pharmacology, no drug is truly "specific" (acting on only one receptor); most are "selective" (preferring one receptor over others). However, at higher doses, selectivity is often lost. * **Therapeutic Index (TI):** A measure of drug safety ($TI = LD_{50} / ED_{50}$). Drugs with high specificity usually have a wider therapeutic index. * **Example:** **Atenolol** is a cardioselective $\beta_1$ blocker. It has higher specificity for heart receptors than **Propranolol** (non-selective), thus minimizing side effects like bronchospasm (mediated by $\beta_2$ receptors).

Question 174: Na+ and/or IC+ are involved in the mechanism of action of which of the following receptors?

A. 5-HT3 receptor
B. Nm receptor
C. Nn receptor
D. All (Correct Answer)

Explanation: **Explanation:** The question focuses on **Ionotropic receptors** (Ligand-gated ion channels), which are cell surface receptors that act as pores, allowing the rapid flow of ions across the cell membrane upon ligand binding. **1. Underlying Concept:** All three receptors mentioned (5-HT3, Nm, and Nn) belong to the family of **Cys-loop ligand-gated ion channels**. Unlike G-protein coupled receptors (GPCRs) which act via second messengers, these receptors are non-selective cation channels. When an agonist binds, the channel opens, allowing the influx of **Sodium (Na+)** and sometimes the efflux of **Potassium (K+)** or influx of Calcium (Ca2+). This rapid movement of ions leads to membrane depolarization and an excitatory response. **2. Analysis of Options:** * **5-HT3 Receptor:** This is the *only* ionotropic serotonin receptor (others are GPCRs). It is located in the Chemoreceptor Trigger Zone (CTZ) and the GI tract. Activation leads to Na+ and K+ conductance, mediating the emetic reflex. * **Nm (Muscle-type Nicotinic) Receptor:** Located at the Neuromuscular Junction (NMJ). Binding of Acetylcholine (ACh) causes Na+ influx, leading to the End Plate Potential (EPP) and muscle contraction. * **Nn (Neuronal-type Nicotinic) Receptor:** Located in autonomic ganglia and the adrenal medulla. Activation causes Na+ influx, resulting in post-ganglionic impulse generation. **3. High-Yield Clinical Pearls for NEET-PG:** * **Fastest Receptors:** Ionotropic receptors (msec) > GPCRs (sec) > Enzyme-linked (min) > Nuclear receptors (hours/days). * **5-HT3 Antagonists:** Drugs like **Ondansetron** are first-line for chemotherapy-induced nausea and vomiting (CINV). * **GABA-A and Glycine:** These are also ionotropic receptors but are **inhibitory** because they conduct **Chloride (Cl-)** ions, leading to hyperpolarization. * **NMDA/AMPA:** These are ionotropic glutamate receptors involved in excitatory neurotransmission via Na+ and Ca2+.

Question 175: What is the dose of a drug required to produce a specified effect in 50% of the population?

A. Lethal Dose 50 (LD50)
B. Toxic Dose 50 (TD50)
C. Median Dose 50 (MD50)
D. Effective Dose 50 (ED50) (Correct Answer)

Explanation: **Explanation:** The correct answer is **Effective Dose 50 (ED50)**. This concept is derived from the **Quantal Dose-Response Curve**, which plots the fraction of the population that manifests a specific "all-or-none" biological effect (e.g., relief of headache, prevention of seizure) against the dose of the drug. 1. **Why ED50 is correct:** By definition, the Median Effective Dose (ED50) is the dose required to produce a predefined therapeutic effect in 50% of the individuals to whom the drug is administered. It is a measure of the **potency** of a drug in a population. 2. **Why other options are incorrect:** * **Lethal Dose 50 (LD50):** This is the dose required to cause death in 50% of the tested population (usually animal models). It measures the ultimate toxicity of a drug. * **Toxic Dose 50 (TD50):** This is the dose required to produce a specific toxic or adverse effect in 50% of the population. * **Median Dose 50 (MD50):** This is not a standard pharmacological term used to describe drug efficacy or safety in this context. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Index (TI):** Calculated as **LD50 / ED50**. A higher TI indicates a safer drug (e.g., Penicillin), while a lower TI indicates a "Narrow Therapeutic Window" (e.g., Lithium, Digoxin, Warfarin, Phenytoin). * **Standard Safety Margin:** Calculated as **(LD1 / ED99) × 100**. This is a more clinically relevant safety index than TI. * **Potency vs. Efficacy:** ED50 determines potency (lower ED50 = higher potency). However, **Efficacy** (the maximum response a drug can produce) is clinically more important than potency.

Question 176: All of the following drugs can cause an SLE-like syndrome except?

A. Isoniazid
B. Diltiazem
C. Procainamide
D. Penicillin (Correct Answer)

Explanation: **Explanation:** Drug-Induced Lupus Erythematosus (DILE) is an autoimmune phenomenon where certain drugs trigger symptoms mimicking Systemic Lupus Erythematosus (SLE). The correct answer is **Penicillin**, as it is a common cause of Type I (Anaphylactic) and Type IV (Delayed) hypersensitivity reactions, but it is **not** associated with an SLE-like syndrome. **Why the other options are incorrect:** * **Procainamide (Option C):** This is the drug with the **highest risk** of inducing DILE. Up to 80% of patients develop Antinuclear Antibodies (ANA), and about 20% develop clinical symptoms. * **Isoniazid (Option A):** A common anti-tubercular drug known to cause DILE, particularly in "slow acetylators" who metabolize the drug slowly via the NAT2 enzyme. * **Diltiazem (Option B):** While less common than Procainamide or Hydralazine, Calcium Channel Blockers like Diltiazem are recognized triggers for cutaneous and systemic drug-induced lupus. **High-Yield Clinical Pearls for NEET-PG:** 1. **Hallmark Antibody:** The most specific marker for DILE is **Anti-Histone Antibodies** (present in >95% of cases). Unlike idiopathic SLE, Anti-dsDNA antibodies are usually absent. 2. **Metabolism Link:** Drugs causing DILE are often metabolized by **Acetylation**. Slow acetylators are at a significantly higher risk. 3. **Key Differences:** DILE typically spares the CNS and Kidneys (unlike idiopathic SLE) and symptoms usually resolve upon discontinuation of the offending drug. 4. **Mnemonic (HIP):** **H**ydralazine, **I**soniazid, **P**rocainamide (The "Big Three" most frequently tested). Other triggers include Chlorpromazine, Methyldopa, and Quinidine.

Question 177: What is the action of Adrenergic 2 receptors and 1 receptors on adenyl cyclase?

A. Stimulate; Stimulate
B. Stimulate; Inhibit
C. Inhibit; Inhibi
D. Inhibit; Stimulate (Correct Answer)

Explanation: This question tests your knowledge of **G-protein coupled receptor (GPCR)** signaling pathways, a high-yield topic for NEET-PG. ### **Mechanism of Action** Adrenergic receptors are classified based on the type of G-protein they are coupled with: 1. **$\beta_1$ Receptors:** These are coupled to **$G_s$ (Stimulatory)** proteins. When an agonist binds to a $\beta_1$ receptor, it activates the enzyme **Adenyl Cyclase**, which converts ATP to cyclic AMP (cAMP). This increase in cAMP mediates effects like increased heart rate and contractility. 2. **$\alpha_2$ Receptors:** These are coupled to **$G_i$ (Inhibitory)** proteins. Activation of $\alpha_2$ receptors **inhibits Adenyl Cyclase**, leading to a decrease in intracellular cAMP levels. This is why presynaptic $\alpha_2$ receptors act as "auto-receptors" to inhibit further norepinephrine release. ### **Analysis of Options** * **Option D (Correct):** Correctly identifies that $\alpha_2$ inhibits and $\beta_1$ stimulates Adenyl Cyclase. * **Option A:** Incorrect. While $\beta_1$ stimulates, $\alpha_2$ does not; it inhibits. * **Option B:** Incorrect. This reverses the functions of the two receptors. * **Option C:** Incorrect. While $\alpha_2$ inhibits, $\beta_1$ is stimulatory, not inhibitory. ### **NEET-PG High-Yield Pearls** * **Mnemonic (QISS):** * $\alpha_1$ = $G_q$ (Activates Phospholipase C) * $\alpha_2$ = $G_i$ (Inhibits Adenyl Cyclase) * $\beta_1, \beta_2, \beta_3$ = $G_s$ (Stimulates Adenyl Cyclase) * **Clinical Correlation:** **Clonidine** is a centrally acting $\alpha_2$ agonist used in hypertension to decrease sympathetic outflow by inhibiting cAMP production in the brainstem. * **Heart & Kidney:** $\beta_1$ receptors are primarily located in the heart (increasing HR/force) and the juxtaglomerular cells (stimulating renin release).

Question 178: Which of the following terms best describes the antagonism of the bronchoconstrictor effect of leukotrienes (mediated at leukotriene receptors) by terbutaline (acting at adrenoceptors) in a patient with asthma?

A. Pharmacologic antagonist
B. Partial agonist
C. Physiologic antagonist (Correct Answer)
D. Chemical antagonist

Explanation: **Explanation:** The correct answer is **Physiologic antagonist (Option C)**. **1. Why it is correct:** Physiologic (or functional) antagonism occurs when two drugs act on **different receptors** to produce **opposing physiological effects** on the same biological system [1]. In this scenario: * **Leukotrienes** act on leukotriene receptors to cause bronchoconstriction [4]. * **Terbutaline** acts on $\beta_2$-adrenoceptors to cause bronchodilation [1], [3]. Because they achieve opposite results (constriction vs. dilation) through independent pathways, they are physiologic antagonists. **2. Why the other options are wrong:** * **Pharmacologic antagonist (A):** This involves a drug binding to the **same receptor** as the agonist to block its action (e.g., Montelukast blocking leukotriene receptors). * **Partial agonist (B):** This is a drug that binds to the same receptor as a full agonist but produces a sub-maximal response (e.g., Pindolol at $\beta$-receptors) [2]. * **Chemical antagonist (D):** This occurs when two substances react **chemically** with each other in solution, neutralizing the drug before it reaches a receptor (e.g., Protamine neutralizing Heparin or Chelating agents). **Clinical Pearls for NEET-PG:** * **Classic Example:** Histamine (H1 receptors) vs. Adrenaline ($\beta_2$ receptors) in anaphylaxis is the most frequently tested example of physiologic antagonism. * **Glucagon vs. Insulin:** These are physiologic antagonists regarding blood glucose levels. * **Key Distinction:** Unlike competitive antagonism, physiologic antagonism cannot be fully overcome by simply increasing the dose of the agonist, as the mechanisms are independent.

Question 179: After oral administration, what is the fraction of a drug that reaches the systemic circulation in unchanged form?

A. Elimination
B. Distribution
C. Bioavailability (Correct Answer)
D. Metabolism

Explanation: ### Explanation **Correct Option: C. Bioavailability** Bioavailability is defined as the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For most clinical purposes, it refers to the **fraction ($f$) of an administered dose** that reaches the **systemic circulation** in an unchanged form. * When a drug is given **intravenously (IV)**, its bioavailability is **100%** ($f=1$). * When given **orally**, bioavailability is often less than 100% due to incomplete absorption and **first-pass metabolism** in the gut wall and liver. **Why other options are incorrect:** * **A. Elimination:** This refers to the irreversible removal of a drug from the body via excretion (e.g., urine, bile) or metabolic biotransformation. * **B. Distribution:** This is the process by which a drug reversibly leaves the bloodstream and enters the interstitium and/or the cells of the tissues. * **C. Metabolism:** Also known as biotransformation, this is the chemical alteration of the drug in the body (primarily by the liver) to convert it into more hydrophilic metabolites for easier excretion. **High-Yield Clinical Pearls for NEET-PG:** 1. **First-Pass Effect:** Drugs with high first-pass metabolism (e.g., Nitroglycerin, Propranolol, Lidocaine) have low oral bioavailability and are often given via sublingual or parenteral routes. 2. **Bioequivalence:** Two pharmaceutical products are bioequivalent if their rates and extents of absorption (AUC, $C_{max}$, and $T_{max}$) do not show a significant difference. 3. **Calculation:** Bioavailability ($f$) = (AUC oral / AUC IV) × 100. 4. **Area Under the Curve (AUC):** This is the most reliable measure of the total amount of drug that reaches the systemic circulation.

Question 180: Which of the following drugs contains disulfide groups?

A. BAL (Correct Answer)
B. EDTA
C. Penicillin
D. Penicillamine

Explanation: **Explanation:** The correct answer is **BAL (British Anti-Lewisite)**, also known as **Dimercaprol**. **1. Why BAL is correct:** BAL is a chelating agent developed during WWII as an antidote for arsenic-based chemical weapons. The term "mercaprol" refers to its chemical structure, which contains two **sulfhydryl (-SH) groups** (also known as thiol or disulfide-forming groups). These groups have a high affinity for heavy metals like arsenic, mercury, and lead. By forming a stable, non-toxic heterocyclic ring complex with the metal, BAL prevents the metal from binding to essential cellular enzymes, allowing for renal excretion. **2. Why the other options are incorrect:** * **EDTA (Ethylene Diamine Tetra-Acetic acid):** This is a polyamino carboxylic acid. It chelates metals (primarily lead and calcium) through its nitrogen and oxygen atoms, not sulfur groups. * **Penicillin:** While penicillin contains a thiazolidine ring (which includes a sulfur atom), it does not contain free sulfhydryl or disulfide groups used for chelation. * **Penicillamine:** This is a metabolite of penicillin used in Wilson’s disease. While it contains **one** sulfhydryl group (-SH), it is classified as a monothiol/amino acid derivative, whereas BAL is the classic "dithiol" (disulfide-related) compound emphasized in pharmacology for its specific chemical structure. **3. NEET-PG High-Yield Pearls:** * **BAL Administration:** It is highly lipid-soluble and must be administered via **deep intramuscular (IM)** injection in an oil base (peanut oil). * **Contraindication:** Avoid BAL in patients with **G6PD deficiency** (risk of hemolysis) and **peanut allergies**. * **Specific Use:** BAL is the drug of choice for **acute arsenic** and **mercury poisoning**. It is often used in combination with EDTA for **lead encephalopathy**. * **Memory Aid:** "BAL has two -SH groups" (Dimercaprol = Di + Mercaptan).

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free